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therapyAbstract Purpose: The aim of this study is to investigate efﬁcacy and toxicity of 1 year of
capecitabine metronomic therapy preceded by standard adjuvant chemotherapy in triple-negative
breast cancer (TNBC) patients.
Methods: Between June 2010 and February 2012, 19 women with pathologically proven operable
TNBC, who had received standard adjuvant chemotherapy before were enrolled. Patients received
1 year of oral capecitabine metronomic therapy (650 mg/m2, twice every day), after standard
adjuvant chemotherapy and radiotherapy if indicated. The primary endpoints of this study were
disease-free survival rates (DFS) and safety proﬁle. Secondary end point was overall survival (OS).
Results: The maximal follow-up was 46.6 months with a median of 30.1 months ±11.525 (95% CI;
28.5–33.5 months). The median DFS was 41.7 months ±2.7 (95% CI; 36.5–46.9). No one devel-
oped locoregional recurrence. The actuarial rate of DFS was 88.8% and 82.05% at 2 and 3 years,
respectively. At the time of the analyses, no patients had died and the median OS was not reached.
Treatment-related adverse events were manageable with only 1 patient (5.3%) suffering from Grade
3/4 hand-foot syndrome and another 1 patient (5.3%) suffering from Grade 3 diarrhea. No Grade
3/4 hematologic toxicity was recorded. All patients received full doses of capecitabine throughout
the study and dose reduction was not required in any of our patients.
Conclusion: One year of capecitabine metronomic therapy preceded by standard adjuvant chemo-
therapy, is active and well-tolerated in TNBC patients previously treated with standard adjuvant
chemotherapy.
ª 2014 Production and hosting by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.
Open access under CC BY-NC-ND license.
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Breast cancer (BC) is increasingly recognized as a heteroge-
neous disease exhibiting substantial differences with regard
to biological behavior and requiring distinct therapeutic
interventions. Steroid hormone receptors (HR) such as estro-
gen receptor (ER) and progesterone receptor (PgR) in concert
with the oncogene ErbB-2/human epidermal growth factor
receptor 2 (HER-2) are critical determinants of these BC
subtypes. While HR are thought to mirror a good prognosis
[1], expression of HER-2 has long been understood as an
unfavorable prognostic feature [2]. However, since the
introduction of trastuzumab as a potent therapeutic approach
in HER-2 positive BC, HER-2 expression is perceived as a
favorable predictive rather than negative prognostic factor
[3,4].
Overall, the prevalence of TNBC in large unselected breast
cancer patient cohorts is 11–20% [5,6], whereas in selected
cohorts of patients with advanced BC or patients of African-
American ethnicity, TNBC may be diagnosed among as many
as 23–28% of patients [7,8].
Patients with TNBC have a grim prognosis with a short
PFS and OS [9,10]. Although several studies are defying the
role of biological agents in the management of TNBC [11],
chemotherapy, whose beneﬁts have been clearly demonstrated
in multiple studies, remains the mainstay of the treatment of
these patients in the neoadjuvant, adjuvant, and metastatic dis-
ease setting [12,13].
There is no universally accepted standard chemotherapy
regimen for adjuvant treatment of TNBC, and classical regi-
mens, are currently reasonable choices. Studies that address
novel agents, platinum compounds and different methods of
drug administration are ongoing for the adjuvant treatment
of TNBC, and the results are eagerly awaited [14].
Capecitabine mimics continuous infusion of 5-FU [15], and
the oral formulation meets with a high degree of acceptance by
both patients and physicians [16]. In metastatic breast cancer,
the registered monotherapy dose has never been compared
with lower doses in a randomized trial, but data from retro-
spective analyses indicate that dose reduction does not impair
efﬁcacy [17], and that lower doses actually have a more
favorable therapeutic index than the standard dosage [18,19].
Metronomic regimens involve the frequent (daily, or several
times a week, or weekly) or continuous administration of che-
motherapy agents at low doses, without lengthy drug free
breaks. This approach is known to enhance the antiangiogenic
activity of these drugs [20,21]. Protracted exposure to low
doses of conventional cytotoxic drugs also offers important
advantages in terms of signiﬁcantly reduced toxicity [22]. Its
pharmacokinetic characteristics and low toxicity proﬁle make
capecitabine an ideal drug for metronomic administration
[23]. In two small randomized trials, continuous use of low
dose capecitabine (650 or 800 mg/m2 b.i.d. with no drug-free
breaks) proved to be just as effective in MBC patients as
intermittent use of higher doses (1000 or 1250 mg/m2 b.i.d.
days 1–14 every 21 days) [24,25].
On the basis of this evidence, we initiated this study to
investigate the tolerability, and survival in patients with oper-
able TNBC who received 1 year of metronomic capecitabine
(650 mg/m2, twice every day) preceded by standard adjuvant
therapy.Materials and methods
Patient eligibility criteria
Between June 2010 and February 2012, 19 women with path-
ologically proven hormone receptor-negative, HER2-negative
(triple receptor negative) breast cancer, were enrolled in
Clinical Oncology Department, Tanta University Hospital.
Patients were followed up until July 2014. At the time of
analysis, the median follow up duration was 30.1 months
(Range; 28.5–46.6 months).
All patients had operable, node-positive breast cancer (or
node negative with tumor diameter P1 cm). Patients fulﬁlled
the following criteria: – age between 18 and 70 years, Eastern
Cooperative Oncology Group (ECOG) performance status
(PS) of 62, adequate bone marrow reserve (WBC count
P3.5 · 109/L, ANC count P1.5 · 109/L, platelets P100 ·
109/L, and hemoglobin P10 g/dL), adequate renal function
(measured creatinine clearance P60 mL/min) and adequate
liver function (transaminases less than 2 · upper normal limit,
and serum bilirubin concentrations below 1.5 mg/dL).
Patients were ineligible for this study if they had metastases
to distant sites, or patients who were pregnant or have demen-
tia, altered mental status, or any psychiatric condition that
would prohibit the understanding or rendering of informed
consent were excluded from this study. Also, patients suffering
from secondary malignancy or concurrent serious, uncon-
trolled medical illness (e.g. persistent immune-compromised
states, uncontrolled infection, and clinically signiﬁcant cardiac
disease) were not eligible.
Design of the study
This study is a prospective single-arm phase II single institution
study. The Ethics Committee in Faculty of Medicine, Tanta
University, granted protocol approval and all patients signed
an informed consent before the initiation of any treatment.
Treatment plan and dose medication
Eligible patients received standard adjuvant chemotherapy
that included anthracycline, either, in the form of FAC,
FEC, or sequential FEC with taxanes followed by radiother-
apy if indicated. After conﬁrmation of immunohistochemistry
status, patients received 1 year of oral capecitabine (Xeloda)
metronomic therapy (650 mg/m2, twice every day).
Oral capecitabine (Xeloda) metronomic therapy is discon-
tinued in case of disease progression or major toxicities.
Chemotherapy is administered on an outpatient basis.
Adequate hematological and within normal range organ
functions were insured every month. Adverse events were
monitored throughout the study. A complete resolution of
hematologic and non-hematologic toxicities was required
except for alopecia and fatigue. If toxicities did not resolve,
then a 1–2 week delay was allowed.
Patient assessment
Pre- and on-treatment monitoring consisted of medical history,
physical and local examination, mammography, chest X-ray,
Table 1 Patients’ and tumor characteristics as well as initial
treatment modality of the 19 TNBC patients managed by
1 year capecitabine metronomic therapy.
































Breast conserving surgery (BCS) 8 (42.1%)
Modiﬁed radical mastectomy (MRM) 11 (57.9%)
Type of adjuvant chemotherapy
FAC 4 (21.1%)
FEC 5 (26.3%)





Capecitabine metronomic chemotherapy 197abdomen and pelvis ultrasonography and/or CT scans, and
bone marrow reserve, renal function and liver function mea-
surement. Toxicity grading was based on the common termi-
nology criteria for adverse event (NCI-CTC, version 3.0) [26].
Primary and secondary endpoints
The primary endpoints of this study were disease-free survival
rates and safety proﬁle. Secondary end point was overall
survival.
Statistical analysis
Overall-survival (OS) rates were calculated from the date of
start of treatment to the time of the last follow-up visit or
death using the Kaplan–Meier method [27] with SPSS
[Statistical package] (version 12.0). Disease-free survival
(DFS) was the time elapsed from the date of initiation of treat-
ment to the date of ﬁrst evidence of disease relapse or death in
the absence of disease relapse. Kaplan–Meier method [27] is
used for estimating survival. 95% conﬁdence intervals (95%
CIs) were calculated with the exact method.
Results
Patient characteristics
Nineteen patients with pathologically proven operable,
node-positive (or node negative with tumor diameter
P1 cm), hormone receptor-negative, HER2-negative (triple
receptor negative) breast cancer were enrolled in this study.
The baseline demographic and clinical characteristics of all
enrolled patients are listed in table 1.
The median age at disease diagnosis was 50.9 years (range
29–70 years), in which 12 (63.2%) patients were postmeno-
pausal and 7 (36.8%) patients were premenopausal. The major-
ity of patients had invasive ductal carcinoma (89.5%) and
grade III disease (68.4%). T 2 disease constituted 57.8% of
all patients at initial presentation prior to any treatment. Most
of the patients (94.7%) had ECOG performance status score of
61. Eleven patients (57.9%) underwent mastectomy for their
primary tumor, and 8 patients (42.1%) underwent a segmental
resection. All patients received adjuvant combination chemo-
therapy and 10 (52.6%) patients received adjuvant radiation
therapy following surgery and combination chemotherapy.
All patients had triple receptor negative breast cancer (TNBC).
Treatment administration
All patients received 1 year of oral capecitabine (Xeloda) met-
ronomic therapy (650 mg/m2, twice every day). The last patient
ﬁnished capecitabine metronomic therapy in August 2013. No
dose reduction was recorded and only 2 patients had a dose
delay of 1 week because of Grade 3 diarrhea (1 patient) and
Grade 3/4 hand-foot syndrome (1 patient).Toxicity
To date, the main forms of adverse reactions to this regimen
observed in the 19 assessable patients are listed in table 2. Mostof hematologic and non-hematological toxicities were mild and
manageable. No Grade 3/4 hematologic toxicity was recorded.
Hand-foot syndrome, a frequent side effect of capecitabine
(Xeloda), was the most common treatment-related adverse
event, occurring in 15.8% (3/19) of patients. Two (10.5%) of
them were of Grade 1/2 hand-foot syndrome while, only 1 case
(5.3%) had Grade 3/4 hand-foot syndrome, which was rapidly
resolved to grade 0/1 with rest and symptomatic treatment.
Diarrhea was experienced by 2 patients (10.5%) with one of
them (5.3%) suffering from grade 3 toxicity. Other grade 1/2
non-hematologic toxicities observed were nausea/vomiting in
2 patients (10.5%) and fatigue in 1 patient (5.3%).
Table 2 Hematologic and non-hematologic toxicities of
capecitabine metronomic therapy used in the management of
19 patients with TNBC.
Toxicity Grade 1/2 No. (%) Grade 3/4 No. (%)
Non-hematologic toxicity
Hand-foot syndrome 2 (10.5%) 1 (5.3%)
Diarrhea 1 (5.3%) 1 (5.3%)
Nausea/vomiting 2 (10.5%) 0.0
Fatigue 1 (5.3%) 0.0
Hematologic toxicity
Anemia 6 (31.6) 0.0















Figure 1 Disease free survival among all patients with triple
receptor negative breast cancer (n= 19).
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diarrhea. All patients received full doses of capecitabine
throughout the study and dose reduction was not required in
any of our patients. However, only 2 patients had a dose delay
of 1 week because of Grade 3 diarrhea (1 patient) and Grade
3/4 hand-foot syndrome (1 patient).
Survival
All our patients were followed up regularly as mentioned pre-
viously in patients and methods, with no one lost to follow up
in this study. The maximal follow-up was 46.6 months with a
median of 30.1 months (Range; 28.5–46.6 months).
At the time of this analysis, 16 of 19 patients had not yet
experienced either intra- or extracranial distant metastases.
In 3 patients, distant metastases were recorded: 2 patients for
extracranial-only visceral disease progression and 1 patient
for distant metastases both at intra- and extracranial visceral
sites. No one developed locoregional recurrence. Among our
19 TNBC patients, the actuarial rate of DFS was 88.8% and
82.1% at 2 and 3 years, respectively, (Fig. 1). At the time of
the analyses, no patients had died.Discussion
Triple negative breast cancer (TNBC) is an aggressive disease
characterized by a lack of expression of both estrogen recep-
tors, and progesterone receptors, as well as human epidermal
growth factor receptor 2 (HER2) [9]. Several studies have
shown that TNBC is associated with an increased response
rate to systemic chemotherapy [13,28,29], and improvements
in chemotherapy are likely to preferentially beneﬁt this subtype
of breast carcinoma because of rapid proliferation rates and
defects in DNA repair. However, there is no preferred
standard form of chemotherapy for TNBC [30].
Other strategies have been adopted to improve the clinical
outcome of patients with TNBC. Bevacizumab [anti-vascular
endothelial growth factor (VEGF) monoclonal antibody] has
been evaluated in patients with TNBC [31–34]. Antiangiogenic
therapy has been studied in large phase III clinical trials as
ﬁrst-line [35,36] and second-line [37] treatment of metastatic
breast cancer. Adjuvant bevacizumab in combination with tax-
anes is being prospectively investigated in TNBC in the BEA-
TRICE trial with the estimated study completion date being
January 2015 [14].
Epidermal growth factor receptor (EGFR)-targeted agents
are being studied in TNBC given a high-level EGFR ofexpression in some of these cancers [38,39]. EGFR inhibitors
have demonstrated low efﬁcacy as single agents in TNBC,
but in combination may improve the efﬁcacy of other agents,
such as taxanes or platinums. However, these agents have a
limited role and could not be used widely for TNBC patients
in our country because of limited resources.
There are several ongoing studies that include phase III tri-
als which explore the addition of capecitabine to standard
adjuvant chemotherapy, or through introduction of mainte-
nance therapy [40–42].
Capecitabine is an oral ﬂuoropyrimidine carbamate that
acts as a 5-ﬂuorouracil (5-FU) prodrug and mimics continuous
infusion of 5-FU [15]. Patients often prefer the convenience of
an oral treatment to intravenous chemotherapy [14,16]. Cape-
citabine has been investigated in the adjuvant setting for the
prevention of breast cancer recurrence [43,44].
In the past few years several studies have emphasized the
role of metronomic chemotherapy to be used as extended adju-
vant chemotherapy [45]. Some metronomic regimens can have
surprisingly potent antitumor effects in preclinical models
compared with respective maximum tolerated dose (MTD)
regimens, despite being less toxic [46].
Because of the high variability of the extended adjuvant
capecitabine treatment dose ranging from a tenth to a third
of the maximum tolerated dose [47] we designed this phase
II trial to investigate the efﬁcacy and tolerability of 1 year of
capecitabine (Xeloda) metronomic therapy at a dose of
650 mg/m2, twice every day as extended adjuvant in newly
diagnosed TNBC who received standard adjuvant chemother-
apy followed by radiotherapy if indicated. The primary end-
points of this study were DFS and safety proﬁle. Secondary
end point was OS.
To our knowledge, this is the ﬁrst prospective study to assess
1 year metronomic capecitabine in patients with operable
TNBC in our country. Our study conﬁrms the overall accept-
able tolerability of extended adjuvant capecitabine. The
extended adjuvant capecitabine treatment phase did not appre-
ciably increase the incidence of hematologic and non-hemato-
logic toxicity compared with previous reports administering
extended adjuvant capecitabine to MBC patients [48–50].
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observed in our 19 assessable patients were mild and manage-
able. No Grade 3–4 hematologic toxicity was recorded.
Hand-foot syndrome (HFS), a frequent side effect of capecita-
bine (Xeloda), was the most common treatment-related
adverse event, occurring in 15.8% (3/19) of our patients. The
majority of HFS was mild to moderate. There was only 1 case
(5.26%) of Grade 3/4 HFS. Diarrhea was experienced by 2
patients (10.5%) with only 1 patient (5.3%) suffering from
grade 3 toxicity. Other grade 1 or 2 non-hematologic toxicities
observed were nausea/vomiting in 2 patients (10.5%) and fati-
gue in 1 patient (5.3%). Only 1 patient required hospitaliza-
tion, because of grade 3 diarrhea. All patients received full
doses of capecitabine throughout the study. Dose reduction
was not required in any of our patients. Interruption of treat-
ment was decided and performed for 1 week in only 2 patients
because of Grade 3 diarrhea (1 patient) and Grade 3/4
hand-foot syndrome (1 patient).
Most of hematologic and non-hematological toxicities dur-
ing the extended adjuvant capecitabine treatment phase were
better than those of other previous reports [48,50]. Two phase
II trials had studied the toxicity proﬁle of metronomic capecit-
abine in metastatic breast cancer (MBC) patients. Ezz El-Arab
et al. [48] had studied the clinical efﬁcacy and tolerability of
low dose, capecitabine (500 mg twice daily) together with oral
cyclophosphamide (CTX) (at dose of 50 mg once daily) in 60
patients with metastatic breast cancer. The overall regimen
was well tolerated. Myelosuppression, a well-documented side
effect of therapy in particular leucopenia (Grades 1 and 2) was
observed in (17%) patients. Palmar–plantar erythrodythesia,
the most frequently reported non-hematologic adverse events,
were also mild to moderate (Grades 1 and 2 in 36.7% of cases),
and could be readily controlled with the administration of
standard medications. Also in our study hand-foot syndrome,
was the most common treatment-related adverse event, occur-
ring in 15.8% (3/19) of patients, with only 1 case (5.3%) of
Grade 3/4 while in Ezz El-Arab et al. [48] study no grade 3
or 4 toxicity was recorded. The use of lower doses in Ezz
El-Arab et al. [48] study compared to those used in our study
could explain the absence of grade 3 or 4 toxicities in their
study. Vomiting in Ezz El-Arab et al. [48] study was much
higher (28.3%) in comparison to that (10.5%) in our study;
this may be due to the effect of CTX in their study. Diarrhea
in our study was lower (10.5%) in comparison to that (20%) in
the study by Ezz El-Arab et al. [48]. However, in our study
only 1 patient (5.3%) suffered from grade 3 diarrhea, while
in Ezz El-Arab et al. [48] study no grade 3 or 4 toxicity was
recorded. Again this could be explained by the use of lower
doses in Ezz El-Arab et al. [48] study to those used in our
study. In Ezz El-Arab et al. [48] study Grade 3 elevation of
serum transaminases was reported in 8% of patients [48]. In
our study no hepatic toxicity occurred. This difference could
be explained by the addition of CTX to Xeloda in Ezz El-Arab
et al. [48] study as well as their study was conducted in meta-
static patients including those with liver metastasis and the
patients were also heavily pretreated.
In another report published by Fedele et al. [50] evaluating
efﬁcacy and safety of low-dose metronomic chemotherapy
with capecitabine in heavily pretreated patients with metastatic
breast cancer, 60 patients received continuous metronomic
capecitabine monotherapy (1500 mg once a day). Hematologic
toxicity was infrequent and mild. Hand foot syndrome (10%)and diarrhea (7%) were the most common adverse effects, and
vomiting occurred in (2%). There were only three cases of
grade 3 toxicity, all involving hand–foot syndrome [50]. These
results were comparable to our results with no hepatic toxicity
recorded.
Evaluating toxicity resulting from exposure to capecitabine
as a maintenance therapy after standard adjuvant therapy
remains a concern. Two phase III ongoing studies are evaluat-
ing extended adjuvant capecitabine treatment after standard
adjuvant therapy (CIBOMA and SYSCBS-001) [28]. In CIB-
OMA 2004-01/ GEICAM 2003-11 a multicenter, open-label,
randomized phase III trial evaluated the efﬁcacy of extended
adjuvant capecitabine treatment, in operable TNBC. Patients
with operable, TNBC who have received standard adjuvant
chemotherapy were eligible. They were randomized to receive
8 cycles of Capecitabine (1000 mg/m2 bid, d1–14 q21d) (Arm
A) or observation (Arm B) [40].
SYSCBS-001 is an open-label, randomized phase III trial,
evaluating the efﬁcacy of extended adjuvant capecitabine treat-
ment in TNBC. Patients with early TNBC were randomized to
treatment with standard adjuvant chemotherapy followed by
observation or to standard adjuvant chemotherapy followed
by 1 year of extended adjuvant capecitabine treatment
650 mg/m2 twice every day [42].
Our study differs from the previously mentioned trials in
being a prospective one arm phase II study that included only
19 patients with operable, TNBC. However, in this study like
both CIBOMA and SYSCBS-001, patients with T4 and N3
were excluded and all patients received 6 cycles of standard
adjuvant chemotherapy before extended adjuvant capecitabine
treatment.
The dose of capecitabine differs between the CIBOMA trial
[40] and both the SYSCBS-001 trial and our study. In the CIB-
OMA trial patients received a standard dose (not the metro-
nomic dose) of capecitabine 1000 mg/m2 bid, d1–14 q21d for
8 cycles, while in the SYSCBS-001 trial [42] and our study
patients received metronomic capecitabine 650 mg/m2 twice
every day for one year. We choose in this study the lower
SYSCBS-001 trial [42] doses as they are expected to be
associated with more tolerability, lower costs, and lower
burden on our limited national resources.
Unfortunately, there are no published data about the
toxicity proﬁle in the SYSCBS-001 trial till now [42].
In comparison to the CIBOMA safety proﬁle, most of the
adverse effects in our study are lower, this is due to the lower
dose of capecitabine we used. The ﬁrst safety data from the
randomized phase III (CIBOMA 2004-01/GEICAM 2003-
11) trial were published by Lluch et al. in San Antonio cancer
symposium 2010 revealing that more than 75% of patients
were able to continue their treatment as planned with
approximately 15% of patients discontinuing due to toxicity
or withdrawal. Grade 3 or 4 adverse effects were higher in
extended adjuvant capecitabine treatment, hand foot
syndrome 17.4%, diarrhea 2.9%, vomiting 1.0%, and ele-
vated bilirubin 1.0% [41]. This preliminary safety analyses
on 405 patients reported 7 serious adverse events considered
possibly related to capecitabine (hospitalization for grade 2–4
diarrhea in 3 patients; grade 2 thoracic pain, grade 2 arrhyth-
mia, coronary vasospasm and chest pain in 1 patient each)
[14]. However, we are waiting for the ﬁnal results of both
CIBOMA and SYSCBS-001 to compare our results with their
results.
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deaths; the majority of studies indicate a negative impact of
a TN (on the basis of data of thousands of patients) phenotype
on patient prognosis [7,8,13,28,51]. Importantly, the prognos-
tic effect of TNBC is independent of poor grade, nodal status,
tumor size and treatment [51,52]. At the time of this analysis,
in our study, not one of our patients had died. The median
duration of follow-up was 30.1 ± 11.5 months, (range 10.1–
46.6 months).
TNBC has been investigated by a number of investigators
as regards the risk of local relapse after conservative surgery
and radiation. In a study by Haffty et al. [53] reported that
there is no evidence that these patients are at a higher risk of
local relapse after conservative surgery and radiation [53].
Our study conﬁrms the overall good efﬁcacy of extended
adjuvant capecitabine, as in our study, none of our patients
developed locoregional relapse whether treated by conserva-
tive surgery and radiation or MRM with or without adjuvant
radiation therapy.
The aggressiveness of TNBC is further indicated by the fact
that (i) the peak risk of recurrence occurs within the ﬁrst
3 years after the initial treatment of the disease with the major-
ity of deaths occurring in the ﬁrst 5 years [54] and (ii) after
diagnosis of metastatic disease, a signiﬁcantly shorter survival
was observed in TNBC [28,55,56].
Our results about the timing of recurrence are comparable
to the data of previous investigators [54], the relapse events in
our study had occurred during the ﬁrst 3 years after diagnosis.
However, our results were promising as only 3 relapse events
have occurred 3/19 (15.8%), with no one developing locore-
gional recurrence, so metronomic capecitabine might be asso-
ciated with decreased incidence of relapse in ﬁrst 3 years in
patients with TNBC. However, these results are preliminary
due to small sample size as well as short follow up period.
Thus, a larger number of patients and longer follow-up period
are necessary.
TNBC has a different pattern of relapse [32]. Several studies
have supported a signiﬁcantly increased rate of visceral versus
bone metastasis [32,57] among patients with TNBC compared
with non-TNBC. In the largest report to date, data on 12 858
patients indicate an increased risk for the lung [odds ratio
(OR) 2.27] and brain (OR 5.32) metastasis as the ﬁrst site of
recurrence and a lower risk of bone recurrence (OR 0.23) in
patients with TNBC [6]. Also, patients with TNBC compared
with other subtypes reportedly experience an increased risk of
central nervous system metastases (CM) of 6–46% of those
experiencing metastatic spread of the disease [49,58,55]. Simi-
larly, in a single-institution study among 3193 patients, a sig-
niﬁcantly elevated risk of CM among patients with TNBC
and HER-2-positive BC compared with other phenotypes
has been reported (HR 4.5 and 4.9 for TNBC and HER-2+,
respectively) [49].
In our study 1 patient (5.3%) from 3 patients (15.8%) who
had developed distant metastases, had intra-cranial disease
metastases. Comparison between our results and the results
of other trials is difﬁcult, because we couldn’t have a ﬁrm
conclusion about the pattern of relapse, due to the small
number of patients and a short follow up period.
Several studies have shown that women with TNBC are at a
higher likelihood of relapse and have an associated poorer
prognosis compared with women with other subtypes of breast
cancer [13,53]. Survival results in our study are encouraging. Inour series, only 3 relapse events have occurred (3/19 (15.8%)),
without development of any locoregional recurrence. At the
time of analyses, no patients had died and median OS was
not reached. Indeed, the actuarial rate of DFS of 88.8% and
82.1% at 2 and 3 years, respectively, compares favorably with
the other previous reported data published in Dawood et al.
[58] study. Dawood et al. [58], studied 679 patients with non-
metastatic TNBC, with median follow-up among all patients
of 26.9 months (range 1.1–321.3 months), two hundred
(29.5%) patients have experienced disease recurrence, and
DFS at 2 and 5 years was 69.2% and 59.6%, respectively. At
the time of this analysis, 153 (22.5%) patients had died and
OS at 2 and 5 years was 85.9% and 64.1%, respectively [58].
So the incidence of both local and distant relapses in our study
was lower in comparison to the previously published data of
Dawood et al. [58] study, but larger samples and longer fol-
low-up are required for better and mature results. However,
our preliminary ﬁndings suggest that metronomic capecitabine
is an active extended adjuvant treatment of patients with
TNBC.
Unfortunately there are no published data about the sur-
vival results of both CIBOMA and SYSCBS-001trials till
now, because they are still ongoing [40].
Conclusion
To our knowledge, this is the ﬁrst report of results of 1 year
extended adjuvant capecitabine therapy in the treatment of
TNBC in our country. The preliminary results of our study
demonstrated that, extended adjuvant capecitabine treatment,
for patients with TNBC is a promising regimen in decreasing
the incidence of both locoregional recurrence and distant
relapse in the ﬁrst 3 years, with acceptable toxicity proﬁle.
Thus, we propose that extended adjuvant capecitabine treat-
ment is an alternative approach with tolerable toxicities for
patients with TNBC, nevertheless, the challenge remains to
improve clinical outcomes further. To conﬁrm this, a multicen-
ter, meta-analysis and a randomized trial with a large number
of patients are required in the near future.Conﬂict of interest
We have no conﬂict of interest to declare.
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